About Us Our Company | Our board
Our Board
Elaine Warburton | Chief Executive Officer
An experienced Board Director and entrepreneur with over 25 years’ experience in biotech and healthcare/hospital management; multiple start-ups; raising angel, grant and VC investment and an authority in introducing innovative technologies into mainstream medicine.
Prof Sir John Burn | Medical Director
Professor of Clinical Genetics, Newcastle University, Lead Clinician NHS North East, Genetics Lead, UK National Institute of Health Research, Innovation Chair, UK Human Genomics Strategy Group, Chair, British Society for Human Genetics. Founder member of the UK Human Genetics Commission and former President of the European Society of Human Genetics.
Jonathan O’Halloran | Chief Scientific Officer
Inventor of QMDx’s proprietary nucleic acid preparation, amplification, detection and sequencing technologies with over 15 years’ experience in scientific research and biotechnology, clinical laboratories and clinical management.
Julian Warburton | Chief Finance Officer
Finance with over 25 years’ experience in Corporate Finance, Banking and Treasury Risk Management for FTSE 100 companies ranging from international banks, fund management, beverages, industrial, pharmaceutical, insurance, product testing and certification.
Sam Whitehouse | Chief Operating Officer
Over 10 years’ biotech and medical devices experience including industrial research, managing a large portfolio of academic-industry biotech collaborations and managing UK government grant portfolios. Synthetic and surface chemist specialist.
Paul J. Fitzpatrick | Non Executive Director & Advisor (USA)
25 years’ entrepreneurial experience – healthcare services, medical devices; 15 years C-Level leadership; multiple startups, early stage, small to mid-size growth companies, roll-ups, turnarounds, 20 M&A transactions; has participated in raising over $30 million in private equity and VC financings.
Stephen Osborne | Research Director
Founder of Pastel BioScience and inventor of InVenio™ technology; 20 years’ in the biotech industry including R&D Manager for a major European diagnostics manufacturer, 3 years as Investment Analyst for a London stock broking company and multiple years raising capital and developing the InVenio™ technology.
The company engages with a large number of independent scientific, medical and commercial advisors to support every aspect of its operations. The company’s technology has been extensively peer reviewed.